Benefits of hepatitis C virus treatment: A balance of preventing onward transmission and re-infection

Mathematical Biosciences

Volumn 258, Issue , 2014, Pages 11-18

  de Vos, A S ^a   Kretzschmar, M E E ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Epidemiology; Hepatitis C virus; Injecting drugs; Mathematical modelling; Treatment as prevention

Indexed keywords

EPIDEMIOLOGY; MATHEMATICAL MODELS; SYRINGES; TRANSMISSIONS; VIRUSES;

HEPATITIS C VIRUS; INJECTING DRUGS; RE-INFECTION; RISK BEHAVIOR; THRESHOLD-VALUE; TREATMENT AS PREVENTION; TREATMENT DURATION; TREATMENT POLICIES;

CURING;

DISEASE TRANSMISSION; DISEASE TREATMENT; DRUG USER; EPIDEMIOLOGY; HEPATITIS; INFECTIOUS DISEASE; MODELING;

ARTICLE; BEHAVIOR CHANGE; CALCULATION; HEPATITIS C; HIGH RISK BEHAVIOR; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MORTALITY; NONHUMAN; PREVALENCE; PROBABILITY; REINFECTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEM ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE; VIRAL CONTAMINATION; VIRUS TRANSMISSION; HUMAN; THEORETICAL MODEL; TRANSMISSION;

HEPATITIS C VIRUS;

HEPATITIS C; HUMANS; MODELS, THEORETICAL;

EID: 84920530921     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2014.09.006     Document Type: Article

References (13)

1. Hagan H., Des Jarlais D.C. HIV and HCV infection among injecting drug users. Mt. Sinai J. Med. 2000, 67:423-428.
2. Hagan L.M., Schinazi R.F. Best strategies for global HCV eradication. Liver Int. 2013, 33:68-79.
3. B. Malhotra (Ed.), The Strategic Use of Antiretrovirals for Treatment and Prevention of HIV Infection: 2nd Expert Panel Meeting Meeting Report. WHO/HIV/2013.
4. Martin N.K., Vickerman P., Foster G.R., Hutchinson S.J., Goldberg D.J., Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J. Hepatol. 2011, 54:1137-1144.
5. Martin N.K., Pitcher A.B., Vickerman P., Vassall A., Hickman M. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One 2011, 6. e22309.
6. Hellard M.E., Jenkinson R., Higgs P., Stoové M.A., Sacks-Davis R., Gold J., Hickman M., Vickerman P., Martin N.K. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria. Med. J. Aust. 2012, 196:638-641.
7. Durier N., Nguyen C., White L.J. Treatment of hepatitis C as prevention: A modeling case study in Vietnam. PLoS One 2012, 7(e34548).
8. Martin N.K., Vickerman P., Miners A., Foster G.R., Hutchinson S.J., Goldberg D.J., Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012, 55:49-57.
9. Zeiler I., Langlands T., Murray J.M., Ritter A. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend. 2010, 110:228-233.
10. Vickerman P., Martin N., Hickman M. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend. 2011, 113:83-85.
11. de Vos A.S., van der Helm J.J., Prins M., Kretzschmar M.E. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users. Epidemics 2012, 4:57-67.
12. Oliver A. A normative perspective on discounting health outcomes. J. Health Serv. Res. Policy 2013, 18:186-189.
13. Kaplan E.H., Heimer R. A circulation theory of needle exchange. AIDS 1994, 8:567-574.